↓ Cooling
Business
UniQure’s gene therapy continues to slow Huntington’s progression after four years
UniQure shares tumble significantly as clinical trial data for its Huntington’s gene therapy draws conflicting reports.
Uniqure
1 trends tracked about this subject — the full history, oldest to newest below.